The purpose of this document is to provide interim guidance to laboratories and stakeholders involved in laboratory testing for Middle East respiratory syndrome coronavirus (MERS-CoV).
doi: 10.9745/GHSP-D-16-00226; Glob Health Sci Pract December 23, 2016 vol. 4 no. 4 p. 626-646
British Journal of Medicine & Medical Research
11(4): 1-6, 2016, Article no.BJMMR.21444
ISSN: 2231-0614, NLM ID: 101570965
Published 27th September 2015
British Journal of Medicine & Medical Research
11(4): 1-6, 2016, Article no.BJMMR.21444
ISSN: 2231-0614, NLM ID: 101570965
Published 27th September 2015
PLOS ONE | DOI:10.1371/journal.pone.0142290 November 9, 2015; 1 / 16
ACAPS Briefing Note: Zika virus epidemic
Independent Monitoring Board of the Global Polio Eradication Initiative (Twelfth Report: October 2015)
Bulletin of the World Health Organization, http://dx.doi.org/10.2471/BLT.16.178608
This document provides interim recommendations for the surveillance of Zika virus infection, microcephaly and Guillain-Barré syndrome, in four different contexts and describes reporting requirements to WHO. Transmission refers to vector-borne transmission, unless specified differently. Autochthonou...s infection is considered to be an infection acquired in-country, i.e. among patients with no history of travel during the incubation period or who have travelled exclusively to non-affected areas during the incubation period. This document does not provide guidance on laboratory investigation or vector surveillance.
more
Совместные действия в связи с туберкулезом и злоупотреблением алкоголем в Эстонии
Первый отчет по демонстрационному проекту
Rapid review and case studies from Member States
Conducted November 2011 to February 2012: Summary Report
This summary report has five sections. Following the introduction (Section 1), Section 2 sets out summary findings and recommendations of the assessment team. Section 3 describes the context in which artemisinin resistance is being tackle...d. Section 4 highlights key achievements and enabling factors for the response to artemisinin resistance, whilst Section 5 provides a more detailed discussion of major issues to be addressed.
more
Manual para la primera fase de implementación
Reporting period January 2015 – December 2015
Bucharest, April 2016